Montelukast%252525252525252525252520levocetrizine

# Montelukast and Levocetirizine *(Note: These are two distinct drugs often prescribed as a combination therapy for allergic rhinitis/asthma; no single fixed-dose combination product is universally standard in all regions.)* ## Overview Montelukast is a selective leukotriene receptor antagonist (LTRA) that inhibits airway edema and smooth muscle contraction. Levocetirizine is a non-sedating, potent H1-receptor antagonist (antihistamine). Used together, they provide synergistic relief for allergic rhinitis and comorbid asthma. ## Primary Indications * Allergic rhinitis (perennial and seasonal) * Asthma (as add-on therapy) * Chronic urticaria (labeling for levocetirizine) ## Adult Dosing * **Montelukast:** 10 mg orally once daily in the evening. * **Levocetirizine:** 5 mg orally once daily in the evening. ## Pediatric Dosing * **Ages 6–14 years:** * Montelukast: 5 mg (chewable tablet) once daily. * Levocetirizine: 2.5–5 mg once daily. * **Ages 2–5 years:** * Montelukast: 4 mg (chewable tablet or oral granules) once daily. * Levocetirizine: 1.25 mg once daily. * *Note: Dosing depends on specific regional guidelines and formulations; always consult current local protocols.* ## Dose Adjustments * **Renal Impairment (Levocetirizine):** Dose reduction is required for CrCl < 50 mL/min (e.g., 2.5 mg every 48 hours for CrCl 30–49 mL/min). No adjustment needed for Montelukast. * **Hepatic Impairment:** No dose adjustment defined for either agent; use caution in severe impairment. ## Contraindications * **Hypersensitivity:** Known hypersensitivity to either component or related molecules (e.g., cetirizine/hydroxyzine). * **End-stage Renal Disease:** Levocetirizine is contraindicated in patients with ESRD (CrCl < 10 mL/min) or those undergoing hemodialysis. ## Adverse Effects * **Montelukast:** Neuropsychiatric events (aggression, depression, sleep disturbances/nightmares, suicidal ideation), headache, upper respiratory infection, and rare reports of Churg-Strauss syndrome. * **Levocetirizine:** Somnolence (less than first-generation antihistamines but higher than other second-generation agents), fatigue, dry mouth, nasopharyngitis. ## Key Drug Interactions * **CYP450 Inhibitors:** Potent inhibitors (e.g., gemfibrozil for montelukast) may increase exposure. * **CNS Depressants:** Caution advised with concurrent use of alcohol or other sedative agents when taking levocetirizine. ## Monitoring * **Psychiatric:** Monitor for new or worsening behavior/mood changes (Black Box Warning context for Montelukast). * **Efficacy:** Symptom control (nasal congestion, sneezing, airway resistance). * **Renal:** Serum creatinine should be monitored in patients with impaired renal function on levocetirizine. ## Clinical Pearls * **Black Box Warning:** The FDA requires a boxed warning for Montelukast due to the risk of serious neuropsychiatric events. It should only be used for allergic rhinitis if other treatments are ineffective or not tolerated. * **Timing:** Both medications are best administered in the evening to optimize symptom control for early morning allergic triggers. * **Absorption:** Montelukast oral granules should be administered directly in the mouth or mixed with a spoonful of soft, cold food (e.g., applesauce) and consumed within 15 minutes. *** **Educational Disclaimer:** This information is for educational purposes. Clinical guidelines, local protocols, and product labeling change frequently. Verify all dosages, contraindications, and drug interactions against institutional guidelines and the most current prescribing information (e.g., package inserts or clinical resources like Lexicomp/UpToDate) before ordering or administering these medications.